Stryker Corporation $SYK Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC lifted its holdings in Stryker Corporation (NYSE:SYK) by 36.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,011 shares of the medical technology company’s stock after buying an additional 3,227 shares during the quarter. Intech Investment Management LLC’s holdings in Stryker were worth $4,222,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Godfrey Financial Associates Inc. acquired a new stake in Stryker in the fourth quarter valued at $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the 3rd quarter valued at about $27,000. Strive Asset Management LLC acquired a new stake in shares of Stryker in the third quarter valued at about $30,000. CGC Financial Services LLC purchased a new stake in Stryker during the fourth quarter worth about $29,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Stryker during the third quarter worth about $34,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $299.15 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The business’s fifty day moving average price is $321.00 and its two-hundred day moving average price is $347.64. The stock has a market cap of $114.68 billion, a PE ratio of 34.62, a price-to-earnings-growth ratio of 1.92 and a beta of 0.80. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same period last year, the firm earned $2.84 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analysts Set New Price Targets

SYK has been the subject of a number of research analyst reports. Truist Financial reaffirmed a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Evercore set a $355.00 price target on Stryker in a report on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Needham & Company LLC lowered their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.48.

Insider Activity at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.